Copy For Citation
KUYUCU Y., SENCAR L.
Med Bull Haseki, vol.59, no.1, pp.58-62, 2021 (Peer-Reviewed Journal)
-
Publication Type:
Article / Article
-
Volume:
59
Issue:
1
-
Publication Date:
2021
-
Doi Number:
10.4274/haseki.galenos.2021.6667
-
Journal Name:
Med Bull Haseki
-
Journal Indexes:
TR DİZİN (ULAKBİM)
-
Page Numbers:
pp.58-62
-
Keywords:
Imatinib, liver, ultrastructure, MESYLATE THERAPY, KINASE INHIBITOR, GROWTH-FACTOR, EXPERIENCE
-
Çukurova University Affiliated:
Yes
Abstract
Aim: Imatinib is a protein tyrosine kinase inhibitor that's used as an anticancer drug. In this study, evaluation the effects of different doses of imatinib on liver ultrastructurally and biochemically was aimed.